ZA202101688B - Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain - Google Patents
Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint painInfo
- Publication number
- ZA202101688B ZA202101688B ZA2021/01688A ZA202101688A ZA202101688B ZA 202101688 B ZA202101688 B ZA 202101688B ZA 2021/01688 A ZA2021/01688 A ZA 2021/01688A ZA 202101688 A ZA202101688 A ZA 202101688A ZA 202101688 B ZA202101688 B ZA 202101688B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- joint pain
- pharmaceutical compositions
- compositions suitable
- articular delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731941P | 2018-09-16 | 2018-09-16 | |
| PCT/US2019/051247 WO2020056399A1 (en) | 2018-09-16 | 2019-09-16 | Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202101688B true ZA202101688B (en) | 2024-06-26 |
Family
ID=68084954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2021/01688A ZA202101688B (en) | 2018-09-16 | 2021-03-12 | Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12208104B2 (https=) |
| EP (1) | EP3849522A1 (https=) |
| JP (1) | JP7634476B2 (https=) |
| KR (1) | KR20210060559A (https=) |
| CN (1) | CN112702993A (https=) |
| AU (1) | AU2019339528B2 (https=) |
| BR (1) | BR112021004880A2 (https=) |
| CA (1) | CA3112234A1 (https=) |
| CL (1) | CL2021000627A1 (https=) |
| IL (1) | IL281513A (https=) |
| MX (1) | MX2021003030A (https=) |
| SG (1) | SG11202102400PA (https=) |
| TW (1) | TWI843751B (https=) |
| WO (1) | WO2020056399A1 (https=) |
| ZA (1) | ZA202101688B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3187955A1 (en) | 2020-08-05 | 2022-02-10 | Sheue-Fang Shih | Pharmaceutical composition of intra-articular corticosteroid for pain control |
| WO2024230404A1 (zh) * | 2023-05-05 | 2024-11-14 | 中南大学湘雅医院 | 一种治疗关节疼痛的氢氧化镁纳米粒、其制备方法及应用 |
| TW202519194A (zh) * | 2023-11-03 | 2025-05-16 | 台灣微脂體股份有限公司 | 用於疼痛控制之關節內皮質類固醇的微脂體組成物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050152962A1 (en) * | 2002-06-12 | 2005-07-14 | Metselaar Josbert M. | Composition for treatment of inflammatory disorders |
| EP1371362A1 (en) * | 2002-06-12 | 2003-12-17 | Universiteit Utrecht Holding B.V. | Composition for treatment of inflammatory disorders |
| DK2797601T3 (en) | 2012-02-10 | 2018-06-14 | Taiwan Liposome Co Ltd | PHARMACEUTICAL COMPOSITIONS FOR REDUCING COMPLICATIONS BY Ocular steroid |
| RU2677658C2 (ru) * | 2012-07-05 | 2019-01-18 | Тайвэн Липосом Ко, Лтд. | Способы лечения артрита |
-
2019
- 2019-09-16 AU AU2019339528A patent/AU2019339528B2/en active Active
- 2019-09-16 SG SG11202102400PA patent/SG11202102400PA/en unknown
- 2019-09-16 KR KR1020217011328A patent/KR20210060559A/ko not_active Ceased
- 2019-09-16 TW TW108133237A patent/TWI843751B/zh active
- 2019-09-16 JP JP2021511641A patent/JP7634476B2/ja active Active
- 2019-09-16 WO PCT/US2019/051247 patent/WO2020056399A1/en not_active Ceased
- 2019-09-16 US US17/272,387 patent/US12208104B2/en active Active
- 2019-09-16 BR BR112021004880-4A patent/BR112021004880A2/pt unknown
- 2019-09-16 MX MX2021003030A patent/MX2021003030A/es unknown
- 2019-09-16 CA CA3112234A patent/CA3112234A1/en active Pending
- 2019-09-16 EP EP19779658.4A patent/EP3849522A1/en active Pending
- 2019-09-16 CN CN201980059773.8A patent/CN112702993A/zh active Pending
-
2021
- 2021-03-12 ZA ZA2021/01688A patent/ZA202101688B/en unknown
- 2021-03-15 CL CL2021000627A patent/CL2021000627A1/es unknown
- 2021-03-15 IL IL281513A patent/IL281513A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI843751B (zh) | 2024-06-01 |
| JP7634476B2 (ja) | 2025-02-21 |
| US20210338688A1 (en) | 2021-11-04 |
| CL2021000627A1 (es) | 2021-09-10 |
| BR112021004880A2 (pt) | 2021-06-01 |
| IL281513A (en) | 2021-04-29 |
| SG11202102400PA (en) | 2021-04-29 |
| CN112702993A (zh) | 2021-04-23 |
| WO2020056399A1 (en) | 2020-03-19 |
| US12208104B2 (en) | 2025-01-28 |
| JP2022500364A (ja) | 2022-01-04 |
| TW202023569A (zh) | 2020-07-01 |
| MX2021003030A (es) | 2021-05-27 |
| AU2019339528A1 (en) | 2021-04-15 |
| AU2019339528B2 (en) | 2025-01-30 |
| CA3112234A1 (en) | 2020-03-19 |
| KR20210060559A (ko) | 2021-05-26 |
| EP3849522A1 (en) | 2021-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551792A1 (en) | Bi-ligand drug conjugate and use thereof | |
| NZ777871A (en) | Small molecule modulators of il-17 | |
| MX2024001204A (es) | Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con derivados de aceite de pescado para usarse en tratar enfermedades del higado graso. | |
| ZA202101688B (en) | Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain | |
| PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
| EA200870469A1 (ru) | Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| UA98462C2 (ru) | Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| MX2024007642A (es) | Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. | |
| TW200603816A (en) | Risedronate compositions and their methods of use | |
| IL272036B1 (en) | Methods and compositions for treatment of pain using capsaicin | |
| HRP20240812T1 (hr) | Oblici doziranja i terapijska primjena l-4-klorokinurenina | |
| EP4389218A3 (en) | Composition for treating joint disease and kit containing same | |
| PH12022551043A1 (en) | Combination of a cxcr7 antagonist with an s1p1 receptor modulator | |
| BR112014001503A2 (pt) | composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para o tratamento de doenças de pele | |
| ZA202200331B (en) | Naltrexone formulation | |
| ZA202100604B (en) | Methods to reduce complications of intra-articular steroid | |
| PH12020551493A1 (en) | Triazacyclododecansulfonamide (``tcd``)-based protein secretion inhibitors | |
| WO2018136647A3 (en) | Therapeutic use of beta-lactams in hematopoiesis, immuno-oncology therapy, and regulation of lipoprotein and apolipoprotein levels | |
| EA202092944A1 (ru) | Применение пероральных распадающихся таблеток рилузола для лечения заболеваний | |
| NZ767242A (en) | Growth differentiation factor 15 agonist compounds and methods of using the same | |
| AR120453A1 (es) | Combinación de un inhibidor de btk y un inhibidor de mdm2 para el tratamiento del cáncer |